Going Solo Suits Vifor And Its Hopes For Two Blockbusters

15 Mar 2018

Enjoying its independence from Galenica, Switzerland’s third-largest pharmaceutical company believes that Ferinject and Veltassa will help it achieve sales of over CHF2bn by 2020.

Flying — Vifor off to a flying start as an independent company • Source: Shutterstock

After announcing its first full-year results as a standalone company, Vifor Pharma Group has laid out ambitious growth plans to more than double sales by 2020, driven by two potential blockbusters – its injectable iron product Ferinject (ferric carboxymaltose) and the hyperkalemia drug Veltassa (patiromer).

Vifor, Switzerland’s third-largest pharmaceutical company with 2,600 employees (1,200 of whom are based in its home country), has undergone major...